This puts the clinician in an unenviable position where, guided by the Latin maxim “Primum non nocere” (First do no harm), they often decide not to use an SGLT2 inhibitor in patients with diabetes with PAD and/or diabetic foot. This evidence concerns the gene SLC5A2 and diabetes mellitus.